Edition:
United States

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

4.04USD
13 Jan 2017
Change (% chg)

$0.11 (+2.80%)
Prev Close
$3.93
Open
$3.96
Day's High
$4.24
Day's Low
$3.89
Volume
687,190
Avg. Vol
388,816
52-wk High
$5.43
52-wk Low
$1.62

IMMU.OQ

Chart for IMMU.OQ

About

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $428.01
Shares Outstanding(Mil.): 105.94
Dividend: --
Yield (%): --

Financials

  IMMU.OQ Industry Sector
P/E (TTM): -- 46.47 30.92
EPS (TTM): -0.63 -- --
ROI: -111.89 -0.87 14.82
ROE: -- -0.56 16.24

BRIEF-Immunomedics Inc- on Jan. 8, 2017 board increased size of board from 6 members to 7 members

* Immunomedics inc- on january 8, 2017 board increased size of board from six members to seven members- sec filing Source text (http://bit.ly/2iprdwr) Further company coverage:

Jan 12 2017

BRIEF-venBio Select Advisor LLC responds to Immunomedics announcement

* venBio Select Advisor LLC responds to Immunomedics announcement

Jan 10 2017

BRIEF-Immunomedics announces reconstituted board and leadership succession plan

* Immunomedics announces reconstituted board of directors and leadership succession plan

Jan 09 2017

BRIEF-Venbio responds to Immunomedics' postponement of annual meeting

* Venbio responds to Immunomedics' postponement of annual meeting

Nov 29 2016

BRIEF-venBio announces director nominees to Immunomedics' Board

* venBio comments on its recent nomination of four highly-qualified candidates for board of Immunomedics, Inc.

Nov 22 2016

BRIEF-Venbio Select Advisor LLC reports 9 pct stake in Immunomedics - SEC filing

* Venbio Select Advisor LLC reports 9 percent stake in Immunomedics Inc as of Nov. 11 - SEC filing

Nov 16 2016

BRIEF-Immunomedics expands antibody-drug conjugate program to potentially address most of human cancers

* Immunomedics Inc - company to expand its adc program to include liquid tumors

Nov 15 2016

BRIEF-Immunomedics Q1 loss per share $0.17

* Immunomedics announces first quarter fiscal 2017 results and clinical program developments

Nov 02 2016

BRIEF-Immunomedics engages Greenhill & Co. as strategic advisor

* Immunomedics -Engaged Greenhill & Co., Inc. to serve as a strategic advisor primarily to assist in its ongoing efforts to out-license sacituzumab govitecan Source text for Eikon: Further company coverage:

Oct 24 2016

BRIEF-Immunomedics announces new patents for antibody-drug conjugates, vaccines for cancer therapy

* Immunomedics announces new patents for antibody-drug conjugates and vaccines for cancer therapy

Oct 19 2016

Competitors

Earnings vs. Estimates